Read this week’s newsletter free featured article on the need to adopt dihydropyrimidine dehydrogenase (DPD) enzyme deficiency screening before the administration of fluoropyrimidine chemotherapy. The article argues that although the incidence is relatively low, patients who have it are unable to metabolize these drugs and can suffer severe toxicity and even fatal adverse reactions: https://www.ismp.org/node/25779